Because these drugs are now widely used in large populations, it would seem appropriate to undertake a large-scale analysis to compare the mortality risks associated with each agent in patients with different clinical indications. Within
A ntagonists of the angiotensin II type 1 receptor (or angiotensin receptor blockers [ARBs] ) reduce the vasoconstrictive and proinflammatory/proproliferative effects of angiotensin II and decrease cardiovascular risk in patients with hypertension alone and those with specific additional risk factors. 1 The US Food and Drug Administration has approved candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, and valsartan, which are now widely used in the treatment of hypertension albeit with different blood pressure (BP)-lowering efficacies. [2] [3] [4] ARBs are indicated in patients with evidence of cardiovascular disease. Several large-scale placebo-controlled trials evaluated the efficacy of ARBs in patients with left ventricular dysfunction, including heart failure (HF) and myocardial infarction. [5] [6] [7] ARBs also prevent or delay the development of end-stage renal disease in patients with diabetes mellitus (DM). 8 More specifically, both losartan and irbesartan slow the progression of renal disease in patients with hypertension with type 2 DM at all stages of diabetic nephropathy. 9, 10 However, recently there have been concerns about an increased cardiovascular risk associated with olmesartan. The Randomized Olmesartan And Diabetes MicroAlbuminuria Prevention (ROADMAP) study reported a higher rate of fatal cardiovascular events with olmesartan compared with placebo among patients with DM with pre-existing coronary heart disease. 11 The Olmesartan Reducing Incidence of Endstage renal disease in diabetic Nephropathy Trial (ORIENT) reported that cardiovascular death was higher in the olmesartan group than in the placebo group. the complex spectrum of cardiovascular disease, the potential differences among ARBs are unexplored largely in terms of arguably the most important clinical end point, mortality. Therefore, the study that follows was designed to use a nationwide retrospective cohort analysis to compare all-cause and cause-specific mortalities among patients treated with the most common ARBs including losartan, valsartan, irbesartan, candesartan, telmisartan, and olmesartan.
Methods

Data Source
A single-payer and compulsory National Health Insurance program was implemented in Taiwan in 1995, and enrollment was 99% by 2010. The Taiwan National Health Insurance database includes complete outpatient visits, hospital admissions, prescriptions, disease, and vital status for 99% of the country's population (≈23 million). The current analyses linked several large computerized claims datasets with the National Death Registry through the use of birth dates and civil identification numbers unique to each beneficiary. The protocol was approved by the National Taiwan University Hospital Research Ethics Committee.
Study Population
From the source population, adult patients aged >20 years were identified who initiated losartan, valsartan, irbesartan, candesartan, telmisartan, or olmesartan therapy between January 1, 2004, and December 31, 2009. All of the ARBs in question were reimbursed by National Health Insurance during that period. Initiation was defined as free of ARB or angiotensin-converting enzyme inhibitor therapy for 12 months before the first prescription (index date). Subjects were excluded if they were (1) ≥100 years of age, (2) without continuous insurance coverage for 12 months before the index date, (3) treated with multiple ARBs/angiotensin-converting enzyme inhibitors on the index date, and (4) diagnosed with cancer before the index date.
Use of Study Drugs
The outpatient pharmacy prescription database was used to obtain prescribed drug types, dosages, date of prescriptions, supply days, and total number of pills dispensed. Every person-day during study period was classified into current use or nonuse. Current use was defined as use during the period between the prescription start date and the end of the days of supply. ARB therapy was classified as discontinued if no medication refill record was available. Patients were allowed to have a grace period of ≤30 days between prescriptions when calculating continuous therapy. Discontinuous treatment patterns resulted in patients contributing person-days into both current use and discontinuation categories. These contributions were only included if the subject survived (no end point).
Outcome Ascertainment
The primary outcome of interest was overall mortality. The vital status and date of death for the study participants were ascertained by linkage through the National Death Registry with a unique identification number. Cause of death was classified further as cardiovascular, cerebrovascular, and cancer death based on the death certificate codes according to the ninth version of the International Classification of Diseases.
Covariate Ascertainment and Adjustment
Inpatient and outpatient diagnosis files and prescription files during the 12-month period before the index date were used to ascertain patients' medical history and pharmaceutical use (Table S1 in the online-only Data Supplement). Demographic data collected included patients' information on age, sex, and resource use (number of outpatient visits, number of hospitalizations, number of laboratory test measurements) 12 months before the index date.
Statistical Analysis
Baseline characteristics, comorbidities, medication use, and resource use among individual ARB initiators were summarized. Person-days of follow-up in each ARB use category were computed for all patients in the cohort. The crude overall and cause-specific mortality rates were calculated, and their 95% confidence intervals (CIs) were estimated based on a Poisson distribution.
In the main analysis, all ARBs users were followed within their initiation groups till the study end as determined by last outpatient visit or hospitalization before December 31, 2010, disregarding any changes in treatment status over time. This intention-to-treat (ITT) analysis preserves the baseline comparability of the treatment groups, reduces the potential bias because of informative switching or discontinuation, and provides a conservative estimate similar to that obtained by an ITT approach in a randomized controlled trial. An analysis using a different follow-up protocol was conducted that censored patients at the point of treatment switching or discontinuation (as-treated [AT] analysis).
A Cox proportional hazards regression model was used to calculate the hazard ratios (HR) and their 95% CI using losartan as the common reference group. Losartan was selected as the reference group because it was the most commonly used ARB in Taiwan. In the multivariable analysis, stepwise selection was used to control for variables with P<0.1 for model entry and >0.05 for removal. Because the number of deaths was small compared with the number of covariates that reflected participant baseline characteristics, comparisons with losartan were conducted and included propensity scores as a summary measure of all these covariates in the regression model to adjust for baseline imbalance. Using separate logistic regression models and losartan as the reference group, a propensity score was estimated with respect to the probability of initiating each ARB other than losartan, as well as age, sex, initiation year, underlying diseases, concomitant medications, and resource use 12 months before the index date. A global heterogeneity test was performed for all ARBs and overall mortality. 13 Separate models were conducted further to estimate the probability of death because of cardiovascular disease, cerebrovascular disease, and cancer.
Auxiliary analyses were then conducted comparing exclusive users who remained on the initial treatment and excluding those participants who were followed <1 year to see whether the results changed substantially.
Stratified analyses were performed to evaluate potential effect modification. Participants were stratified further according to age and other cardiovascular risks. Individual ARBs were compared with losartan in terms of high and low mean defined daily dosages (DDD) category (≥1 DDD/d versus <1 DDD/d) by SAS CONTRAST statement. Mean daily dosage for each individual was calculated by dividing the cumulative dosage by the follow-up duration. Two-sided P<0.05 was considered to be statistically significant. All statistical analyses were performed with SAS 9.2 (SAS Institute, Cary, NC).
Results
A total of 690 463 ARBs initiators were included in the analysis ( Figure 1 ). As identified in Table 1 , groups of ARBs initiators differed in several baseline characteristics. Olmesartan initiators had a higher proportion of hypertension but a lower proportion of DM, ischemic heart disease, myocardial infarction, HF, cerebrovascular disease, and ischemic stroke. They were also more likely to receive calcium channel blockers but less likely to receive antiplatelet and β-blockers therapy. Candesartan initiators had a higher proportion of ischemic heart disease and HF and were more likely to receive statins and nitrates. A higher proportion of both valsartan and irbesartan initiators had prior cerebrovascular disease and ischemic stroke, whereas a higher proportion of irbesartan initiators also had DM and chronic renal disease.
The mean follow-up duration ranged from 2.8 years for olmesartan to 4.1 years for irbesartan. Approximately 70% of the participants discontinued or switched to ARBs other than their original treatment during the study period, resulting in a shorter treatment duration, ranging from 290 days to 425 days in the AT analysis ( Table 2 ). The mean daily dosage was ≈0.4 DDD per day, similar for all ARB groups. The crude overall mortality and predefined cause-specific mortality rates are shown in Table 2 following an ITT approach (following all ARBs users in their initiation groups till the study end) and an AT approach (censoring patients at the point of treatment switching or discontinuation). The global heterogeneity tests were statistically significant for overall mortality in the former (multivariable regression analysis: P<0.001; propensity score analysis: P<0.001) and in the latter (multivariable regression analysis: P=0.036; propensity score analysis: P=0.015).
Results from traditional multivariable Cox regression were similar to those from the model adjusted for baseline propensity scores, although estimations from propensity score analysis were more precise (Table S2 ). In the main analysis by ITT approach (following patients till study end), valsartan initiators were associated with a statistically significant increased risk of overall mortality by traditional multivariable regression analysis (HR, 1.04; 95% CI, 1.02-1.06). In contrast, telmisartan and olmesartan initiators were associated with statistically significant decreased risks of overall mortality; HRs were 0.93 (95% CI, 0.90-0.96) and 0.93 (95% CI, 0.88-0.97), respectively, after adjusting for baseline propensity score. Irbesartan (HR, 0.96; 95% CI, 0.94-0.99) and candesartan (HR, 0.95; 95% CI, 0.92-0.99) initiators also seemed to have decreased overall mortality compared with losartan initiators. For causespecific mortality, telmisartan initiators had decreased risks of cerebrovascular mortality, whereas olmesartan initiators had lower risks of cardiovascular mortality ( Figure 2 ).
Because ITT approach may bias the result toward the null particularly when the crossover rates among comparison groups were high, analyses were also conducted by AT approach that censored patients at ARB discontinuation or switching. Valsartan initiators had a consistently higher risk of overall mortality (HR, 1.23; 95% CI, 1.11-1.37 by traditional multivariable regression and propensity score analysis) and cerebrovascular mortality (HR, 1.82; 95% CI, 1.40-2.37 (Table S2 , bottom, AT approach). Similar results were found in the auxiliary analyses comparing exclusive users and excluding those participants who were followed <1 year (Tables S3 and S4 , respectively).
In the subgroup analysis, the increased overall mortality associated with valsartan initiators seemed to be consistent across subgroups stratified by age, hypertension, DM, HF, coronary heart disease, cerebrovascular disease, chronic renal disease, and dosage (Table S5 , top, ITT approach). Olmesartan was associated with a lower overall mortality risk in the patients with coronary artery disease (HR, 0.90; 95% CI, 0.82-0.99) and in the high-dose users (mean daily dosage ≥1DDD/d; HR, 0.92; 95% CI, 0.87-0.97; Table S5 , top, ITT approach).
Discussion
The results of this study identified statistically significant differences in mortality risk among different ARBs. However, the observed differences were only marginal and thus less likely to be clinically important.
Individual ARBs may differ with respect to their clinical outcomes because of differences in pharmacokinetics and in their affinities for the angiotensin II type 1 receptor. For example, candesartan has a stronger affinity for the receptor and is more effective at lowing BP than losartan. 14, 15 This observation may explain the Swedish Heart Failure Registry finding a lower mortality risk associated with candesartan compared with losartan. 16 In this same regard, other studies demonstrated a greater reduction in BP in those treated with olmesartan compared with losartan and valsartan. 17 BP is one of the most important risk factors for coronary artery disease and stroke. 18, 19 Previous studies showed that candesartan, telmisartan, irbesartan, and olmesartan are superior to losartan in reducing BP. 15, [20] [21] [22] [23] [24] The superior antihypertensive effects might explain the slight reduction in the overall mortality of those 4 above-mentioned ARBs. These observations add circumstantial support to the hypothesis that differences in antihypertensive efficacy may account for the differences in mortality risk. However, some clinical trials suggest that ARBs exert cerebroprotective effects beyond BP lowering. 25, 26 The current results are consistent with prior trials that suggested that telmisartan has unique properties that promote primary and secondary stroke prevention. 27 However, the reason that valsartan and possibly olmesartan were associated with a higher risk of cerebrovascular mortality needs further clarification.
The strength of current study derives from the large sample size and the comparison of multiple ARBs across a wide spectrum of patients with different cardiovascular risks. The mortality outcomes were obtained objectively by linkage through National Death Registry. A new-user design was used to include only ARB initiators who were free of prior angiotensin-converting enzyme inhibitors use to increase baseline homogeneity. 28 Similar results from the crude and multivariable regression analyses suggested that minimal residual confounding existed because all ARBs were used in similar clinical settings as patients were randomized by nature. To overcome the analytic difficulties further, 2 different followup protocols were applied in the survival analysis. The ITT approach retained the original study allocation and followedup for a longer period of time. The analysis always drives the result to null (ie, making the estimated HR closer to 1). The AT approach in which follow-up ended at the point of treatment switching or discontinuation might introduce some potential informative censorship. Another consideration is the use of the different adjustment approach. The propensity score analysis that collapsed information from dozens of baseline covariates into a single score should produce a more precise estimate than the multivariable regression analysis alone. Similar findings were observed when the cohort was restricted to those who remained throughout the study on the initial ARB treatment, excluding those who were followed for <1 year.
Understanding the implications of the different follow-up and adjustment strategies is required to interpret the comparisons between the current study and previous reports successfully. In contrast, the current analysis, even with the most conservative ITT approach, showed that olmesartan was associated with a lower cardiovascular mortality than losartan. However, the AT approach found that olmesartan was associated with a significant elevation in cerebrovascular mortality. The contradictions might result from the informative censorship because of early drug shift or discontinuation inherent in the AT analysis. The CIs were wide because of lack of power.
ARBs are reported to be associated with a modestly increased risk of incident cancer diagnosis, although most of the patients included in the meta-analysis used telmisartan. 29 Other studies, including those conducted by the Food and Drug Administration, assert no increase in risk of cancer.
30
In contrast, patients using telmisartan in the current analyses had a lower risk of cancer mortality than those using losartan. This may reflect a timeframe not sufficient to test the association rigorously. There are several limitations in this study. First, the study design is observational. Although no major differences were noted among the initiators of different ARBs except for olmesartan, some unevaluated patient characteristics might be different. For instance, the degree of BP control may be important in determining the mortality risk within different ARB cohorts. Thus, the moderate beneficial effect of olmesartan versus losartan might be, in part, attributed to differential BP reduction. Furthermore, valsartan has been approved for HF in Taiwan, but olmesartan has not. Confounding by indication might also exist. Second, the claims data did not record some crucial information, such as systolic and diastolic BP before and after ARB use. Therefore, the analyses were not able to distinguish BP-dependent and BP-independent effects. Because BP is an important risk factor for cardiovascular and cerebrovascular mortality and physicians may choose an ARB or shift to different ARBs based on patients' BP responses, one might suggest the need for an alternative method such as one using a marginal structural model to deal with this time-dependent confounding.
31 However, the current findings from both ITT and AT approaches should provide conservative results without making too many assumptions. Third, although other diseases or use of medication such as aspirin or statins after ARB initiation could potentially affect mortality outcomes, they were not associated with ARB discontinuation/switching and, therefore, were unlikely to be important confounders in the observed association. Fourth, because of multiple comparisons conducted in this study, some of the significant results may be false-positive findings. Finally, the ARBs in the early years (mainly losartan and valsartan) were prescribed largely to, and reserved for, high-risk patients who did not tolerate angiotensin-converting enzyme inhibition. Others like irbesartan were niched toward the DM market. By the time telmisartan and olmesartan emerged, the ARBs were better established and more widely used in more routine patients with hypertension. Although the selection process attempted to balance the baseline characteristics among different ARB users, there might be a confounding by indication because of time-or erarelated differences in prescribing trends.
Perspective
The analysis indicates that the differences in overall and cause-specific mortality risk among individual ARBs were only marginal. Although a longer follow-up is warranted clearly, the large cohort suggests that olmesartan does not seem to increase cardiovascular risk compared with losartan. What Is New?
• The analysis from Taiwan's National Health Insurance Research Database showed that valsartan increased the risk of overall mortality only slightly compared with losartan and olmesartan did not seem to increase cardiovascular mortality. The statistically significant differences may be because of uncontrolled confounding and their small size, and the differences may not be clinically important.
What Is Relevant?
• Angiotensin receptor blockers, including losartan, valsartan, irbesartan, candesartan, telmisartan, and olmesartan, are used widely in the treatment of hypertension and other cardiovascular diseases. There has been a concern that olmesartan might be associated with an increased cardiovascular risk. Table S4 . Hazard ratios of overall mortality and cause-specific mortality comparing participants of individual angiotensin receptor blocker with losartan after excluding those who were followed less than 1 year by intention-to-treat approach
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